News

Cornelia Tischmacher with her medical team in Chicago.
Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer ...
OmRx Oncology begins phase 2 trial of oral PD-L1 inhibitor OX-4224 in patients with non-small cell lung cancer: San Diego Saturday, May 10, 2025, 12:00 Hrs [IST] OmRx Oncology, or ...